Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2013; 19(5): 721-726
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Table 2 Follow up of DNA values and cumulative rates of complete and partial virological suppression n (%)
| Month | 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 |
| Patients with DNA | 163 (100) | 158 (96.9) | 141 (86.5) | 121 (74.2) | 105 (64.4) | 76 (46.6) | 56 (34.4) | 24 (14.7) |
| Complete virological suppression | 0/169 (0) | 104/158 (65.8) | 117/141 (83.0 ) | 96/121 (74.4) | 94/105 (89.5) | 65/76 (85.5) | 46/56 (82.1) | 19/24 (79.2) |
| Cumulative CVS | 0% | 66.7% | 88.8% | 85.1% | 94.8% | 93.2% | 92.2% | 91.6% |
| Partial virological suppression | 22/163 (13.5) | 141/158 (89.2) | 133/141 (94.3) | 117/121 (90.7) | 100/105 (95.2) | 75/76 (98.7) | 54/56 (96.4) | 23/24 (95.8) |
| Cumulative PVS | 13.5% | 89.2% | 94.9% | 92.1% | 96.3% | 99.0% | 97.3% | 96.6% |
- Citation: Fahrtash-Bahin F, Kariyawasam VC, Gray T, Byth K, George J, Douglas MW. Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol 2013; 19(5): 721-726
- URL: https://www.wjgnet.com/1007-9327/full/v19/i5/721.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i5.721